Today: Clovis Oncology Inc. (CLVS) Upgrade to “Buy” by Vetr Inc.

Today: Clovis Oncology Inc. (CLVS) Upgrade to “Buy” by Vetr Inc.

Clovis Oncology Inc. (NASDAQ:CLVS) was upgraded by stock analysts at Vetr from a “sell” rating to a “buy” rating in a research report issued on Monday. The firm presently has a $39.27 price target on the biopharmaceutical company’s stock. Vetr‘s price target would indicate a potential upside of 5.06% from the company’s previous close.

Several other equities research analysts also recently commented on CLVS. SunTrust Banks Inc. started coverage on shares of Clovis Oncology in a report on Friday, August 5th. They set a “buy” rating and a $25.00 price objective on the stock. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $13.00 price objective on shares of Clovis Oncology in a report on Tuesday, August 9th. Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Thursday, August 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $30.00 price objective on shares of Clovis Oncology in a report on Thursday, August 18th. Finally, Piper Jaffray Cos. set a $14.00 price objective on shares of Clovis Oncology and gave the company a “hold” rating in a report on Thursday, August 18th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $36.41.

Shares of Clovis Oncology (NASDAQ:CLVS) opened at 37.38 on Monday. Clovis Oncology has a one year low of $11.57 and a one year high of $40.29. The company’s 50 day moving average is $32.24 and its 200 day moving average is $22.69. The company’s market capitalization is $1.44 billion.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.95) by $0.25. During the same quarter in the previous year, the company earned ($2.62) earnings per share. Equities research analysts predict that Clovis Oncology will post ($8.97) earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of CLVS. Rhumbline Advisers boosted its position in Clovis Oncology by 0.8% in the third quarter. Rhumbline Advisers now owns 34,323 shares of the biopharmaceutical company’s stock valued at $1,237,000 after buying an additional 276 shares during the period. BlackRock Inc. boosted its position in shares of Clovis Oncology by 12.4% in the third quarter. BlackRock Inc. now owns 2,875 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 318 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Clovis Oncology by 1.1% in the third quarter. California State Teachers Retirement System now owns 67,345 shares of the biopharmaceutical company’s stock worth $2,428,000 after buying an additional 700 shares during the last quarter. Bourgeon Capital Management LLC boosted its position in shares of Clovis Oncology by 7.2% in the third quarter. Bourgeon Capital Management LLC now owns 14,850 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 1,000 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Clovis Oncology by 3.2% in the second quarter. ProShare Advisors LLC now owns 33,584 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 1,056 shares during the last quarter.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Related posts

Leave a Comment